SLC5A2 and Prader-Willi syndrome: In a 20-year-old woman with PWS, the addition of SGLT2 inhibitor, empagliflozin (10 mg/day) to existing liraglutide therapy resulted in significant improvements in both weight and glycemic control: a weight loss of approximately 5.5 kg (7.4%) was achieved during the subsequent 5 months without altering dietary intake and HbA1c level notably improved from 9.2 to 7.2% [101].